When they were simply trying to find a way to find vaccines to prevent, and treat HIV, the penny stock of GeoVax Labs, Inc. (GOVX) was simply looked at as a poor choice for a long trade, losing more than -50% of its market cap since the start of the year. Dropping from the high .40’s at the start of the year to under .20 for a brief moment in July, GOVX stock needed something to help push it back into the spotlight considering their revenues dropped considerably compared to last year even though their shares trended similarly in 2013 from the mid .70’s. After announcing that they too are throwing their hat into the “find a cure for Ebola” arena, the turn around being witnessed today may have the same life expectancy as an infected person with the disease.
Want to crush the Markets and make profits of $624, $2,897, even $40,656?
Click HERE To Make Sure You Don’t Miss Our Penny Stock Alerts!
GOVX Stock Quote
Market Cap: 8.40M
Last: 0.32 ▲ +0.109 (+51.66%)
Volume: 610,082
Dollar Volume: $174,235
Open: 0.22
High: 0.305
Low: 0.22
Trades: 192
14-Day RSI: 71.29
1st Resistance Point: 0.3367
1st Support Level: 0.2566
52Wk High: 0.97
52Wk Low: 0.19
Ebola and finding a cure or way to treat the disease that was only recognized less than 40 years ago has become one of the hottest catalysts in the stock market right now. We profiled earlier Hemispherx Biopharma, Inc. (HEB) and listed a group of other stocks that are trading hot due to the Ebola catalyst, but GeoVax Labs hadn’t yet gotten involved publicly until their announcement pre-market today that they were going to embark on their own investigation about how to come up with a safe and effective vaccine to prevent infection.
When you have a glance at the balance sheet of GeoVax Labs, an amazing discovery is their almost complete lack of liabilities for a biotech firm whose sole purpose is to, by any means necessary, find a way to treat or cure the clade B subtype of the HIV virus that is most prevalent in the United States and western Europe. Thanks to having funded their activities to date from government grants and clinical trial assistance, as well as some selling of GOVX stock, total liabilities, as of June 30, 2014, were a mere $237,494, roughly $75,000 less than they were at the start of the year.
Interestingly, GeoVax Labs is not without revenues on their income statement, despite being an OTC listed player in the vaccine field. For the 6 months ended June 30, 2014, revenues from government grants were $337,781 compared to $1,238,601 for the same 6 month period in 2013. Although the revenues are obviously from funding programs, the Company’s progress on their HIV studies which stems from technology exclusively licensed from Emory University which was developed in collaboration with the National Institutes of Health and the Centers for Disease Control and Prevention proves that they are serious players and not just news whores trying to get some attention on GOVX.
Thanks to the news announcement today and the low number of issued and outstanding shares, GOVX stock was a great play at the bell, gaining over 50% before the midday break. With volume just now past the half million mark, a strong EOD push once traders see what’s within the Company’s track record for HIV studies, GOVX stock could see themselves closing above their current spot and push, yet again, tomorrow morning to levels not seen since Q1, 2014.
Looking for the Best Penny Stocks to Buy?
Click HERE To Receive FREE Penny Stock Alerts
About GOVX Stock
GeoVax Labs, Inc. is a biotechnology company whose planned principal operations are the design, testing, manufacturing and sale (either directly or through licensees) of vaccines to treat human diseases.
Click here to view the SEC filings for GOVX.
Click here to view the website for GeoVax Labs.
Authorized: 75,000,000
Issued and Outstanding: 25,468,037
Last 5 Trading Sessions:
| Date | Open | High | Low | Last | Change | % Chg | Volume |
| 10/02/14 | 0.2200 | 0.3301 | 0.2200 | 0.3200 | +0.1090 | +51.66% | 610,082 |
| 10/01/14 | 0.2111 | 0.2400 | 0.2110 | 0.2110 | -0.0290 | -12.08% | 62,600 |
| 09/30/14 | 0.2300 | 0.2400 | 0.2230 | 0.2400 | +0.0100 | +4.35% | 14,400 |
| 09/29/14 | 0.2232 | 0.2400 | 0.2231 | 0.2300 | -0.0100 | -4.17% | 2,400 |
| 09/26/14 | 0.2349 | 0.2400 | 0.2349 | 0.2400 | unch | unch | 15,200 |
Bottom Line:
These penny stocks playing in the Ebola arena are going to see initial pops just like what we saw at the start of the year when Company X would mention how they were getting involved in marijuana. GOVX stock has held up nicely through the morning and should be atop the list of Ebola stocks that traders are playing through the end of the week. With a pullback likely to come, those who missed out on the run may want to wait for another pop before jumping in too deep after seeing how poorly GOVX shares have performed since the start of 2013.
Stay Connected With Us:
[gravityform id=”6″ name=”Post” title=”false”]
(We are 100% Anti-Spam and will never rent or sell your information) Although many of our picks go up 100, 200% even 4,000%, there is always the chance a stock could move lower.
Please read and understand our rules very carefully:
1. Penny Stocks can be very dangerous, unless you understand the risk involved with them do not try to trade them. Many go up fast and can drop just as fast;
2. Do not risk too much in one company. You can lose it all very quickly;
3. Do not “marry” any one stock. Recognize if you are wrong about a stock, cut your losses and move on to the next stock; and
4. Always use stop loss orders. We recommend that you use “trailing stops” in order to protect your profits.
OCT
